Skip to main content
SpringerLink
Log in

Mucositis: Prevention and Management

  • Chapter
  • First Online:
Dysphagia Management in Head and Neck Cancers

  • 1338 Accesses

Abstract

Mucositis is defined as inflammation of mucosa as a result of damage to the mucosal lining. Oral erythema, ulceration, and pain are the chief characteristics. It is one of the commonest side effects of radiotherapy (RT) and/or chemotherapy (CT) and is also seen in patients receiving bone marrow transplantation. The severity and duration may vary from patient to patient and may depend on the type and dose of cancer therapeutic agents used [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995–2025.

    Article  Google Scholar 

  2. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66:253–62.

    Article  Google Scholar 

  3. Murphy BA, Beaumont JL, Isitt J, Garden AS, Gwede CK, Trotti AM. Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manag. 2009;36:522–32.

    Article  Google Scholar 

  4. Nonzee NJ, Dandade NA, Markossian T, et al. Evaluating the supportive care costs of severe radio-chemotherapy-induced mucositis and pharyngitis. Cancer. 2009;113:1446–52.

    Article  Google Scholar 

  5. Elting LS, Keefe DM, Sonis ST, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation and impact on quality of life. Cancer. 2008;113:2704–13.

    Article  Google Scholar 

  6. Sonis ST. The pathobiology of mucositis. Semin Oncol Nurs. 2004;20:11–5.

    Article  Google Scholar 

  7. Anthony L, Bowen J, Garden A, Hewson I, Sonis S. New thoughts on the pathobiology of regiment-related mucosal injury. Support Care Cancer. 2006;14:516–8.

    Article  Google Scholar 

  8. Scully C, Epstein JB, Sonis ST. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 1, pathogenesis and prophylaxis of mucositis. Head Neck. 2003;25:1057–70.

    Article  Google Scholar 

  9. Pignon J-P, le Maitre A, Bourhis J. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys. 2007;69:S112–4.

    Article  Google Scholar 

  10. Rosenthal DI, Mendoza TR, Chambers, et al. The MD Anderson symptom inventory–head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis. Int J Radiat Oncol Biol Phys. 2008;72:1355–61.

    Article  Google Scholar 

  11. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.

    Article  CAS  Google Scholar 

  12. Trotti A, Colevas AD, Setser A, et al. CTCAE v3. 0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–81.

    Article  Google Scholar 

  13. US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute. 2009.

    Google Scholar 

  14. https://www.rtog.org/ResearchAssociates/AdverseEventReporting/CooperativeGroupCommonToxicityCriteria.aspx

  15. Cleeland CS. Symptom burden: multiple symptoms and their impact on patient-reported outcomes. J Natl Cancer Inst Monogr. 2007;37:16–21.

    Article  Google Scholar 

  16. Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 2003;39:91–100.

    Article  Google Scholar 

  17. De Sanctis V, Bossi P, Sanguineti G, et al. Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus statements. Crit Rev Oncol Hematol. 2016;100:147–66.

    Article  Google Scholar 

  18. Maciejewski B, Withers HR, Taylor JM, Hliniak A. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. Int J Radiat Oncol Biol Phys. 1989;16:831–43.

    Article  CAS  Google Scholar 

  19. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus Cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.

    Article  CAS  Google Scholar 

  20. Raber-Durlacher JE, Elad S, Barasch A. Oral mucositis. Oral Oncol. 2010;46:452–6.

    Article  Google Scholar 

  21. Scully C, Epstein JB, Sonis ST. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: diagnosis and management of mucositis. Head Neck. 2004;26:77–84.

    Article  Google Scholar 

  22. Rosenthal DI, Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol. 2009;19:29–34.

    Article  Google Scholar 

  23. Clarkson JE, Worthington HV, Eden OB. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007;1:2.

    Google Scholar 

  24. Bensinger W, Schubert M, Ang KK, et al. NCCN Task Force Report. prevention and management of mucositis in cancer care. J Natl Compr Cancer Netw. 2008;6:S1–21.

    Article  CAS  Google Scholar 

  25. Nagarajan K. Chemo-radiotherapy induced oral mucositis during IMRT for head and neck cancer-an assessment. Med Oral Patol Oral Cir Bucal. 2015;20:e273.

    Article  Google Scholar 

  26. Rosenthal DI, Chambers MS, Fuller CD, et al. Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;72:747–55.

    Article  Google Scholar 

  27. Kruser TJ, Rice SR, Cleary KP, et al. Acute hematologic and mucosal toxicities in head and neck cancer patients undergoing chemoradiotherapy: a comparison of 3D-CRT, IMRT, and helical tomotherapy. Technol Cancer Res Treat. 2013;12:383–9.

    Article  Google Scholar 

  28. Sanguineti G, Endres EJ, Gunn BG, Parker B. Is there a “mucosa-sparing” benefit of IMRT for head-and-neck cancer? Int J Radiat Oncol Biol Phys. 2006;66:931–8.

    Article  Google Scholar 

  29. Stokman MA, Spijkervet FK, Burlage FR, et al. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind, randomised clinical trial. Br J Cancer. 2003;88:1012–6.

    Article  CAS  Google Scholar 

  30. McGuire DB, Correa ME, Johnson J, et al. The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer. 2006;14:541–7.

    Article  Google Scholar 

  31. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120:1453–61.

    Article  Google Scholar 

  32. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339–45.

    Article  CAS  Google Scholar 

  33. Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820–31.

    Article  CAS  Google Scholar 

  34. Peterson DE, Öhrn K, Bowen J, et al. Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer. 2013;21:327–32.

    Article  Google Scholar 

  35. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590–8.

    Article  CAS  Google Scholar 

  36. Le QT, Kim HE, Schneider CJ, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol. 2011;29:2808–14.

    Article  CAS  Google Scholar 

  37. Moshkovska T, Mayberry J. It is time to test low level laser therapy in great Britain. Postgrad Med J. 2005;81:436–41.

    Article  CAS  Google Scholar 

  38. Arora H, Pai KM, Maiya A, Vidyasagar MS, Rajeev A. Efficacy of he-ne laser in the prevention and treatment of radiotherapy-induced oral mucositis in oral cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105:180–6.

    Article  Google Scholar 

  39. de Lima AG, Villar RC, de Castro G, et al. Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study. Int J Radiat Oncol Biol Phys. 2012;82:270–5.

    Article  Google Scholar 

  40. Epstein JB, Elad S, Eliav E, Jurevic R, Benoliel R. Orofacial pain in cancer: part II—clinical perspectives and management. J Dent Res. 2007;86:506–18.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India

    R. Anoop

Authors
  1. R. Anoop
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Head and Neck Surgery and Oncology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, India

    Krishnakumar Thankappan

  2. Department of Head and Neck Surgery and Oncology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, India

    Subramania Iyer

  3. Department of Laryngology, Kerala Institute of Medical Sciences, Thiruvananthapuram and Dysphagia Unit, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, India

    Jayakumar R Menon

Electronic Supplementary Material

Patient with stage 1 V carcinoma of the supraglottis on chemoradiotherapy, 5th week showing grade III mucositis (confluent ulcerations or pseudomembranes; bleeding with minor trauma, severe pain; interfering with oral intake; note the feeding tube) (MP4 56272 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Anoop, R. (2018). Mucositis: Prevention and Management. In: Thankappan, K., Iyer, S., Menon, J. (eds) Dysphagia Management in Head and Neck Cancers. Springer, Singapore. https://doi.org/10.1007/978-981-10-8282-5_29

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-8282-5_29

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-8281-8

  • Online ISBN: 978-981-10-8282-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation